中國奧園(03883.HK)奧園健康(03662.HK)急挫15%-24%尋底 確認正初步洽售物業管理附屬
遭評級機構惠譽降長期外幣發行人違約評級至「B+」兼展望負面的中國奧園(03883.HK)與旗下奧園健康生活(03662.HK)就若幹媒體報道聯合聲明確認,奧園健康正與若幹獨立第三方就可能出售提供物業管理及相關服務的若幹附屬權益進行初步討論,惟至今尚未就可能交易訂立任何條款或具體協議,強調可能交易未必會落實。此外,摩通對中國奧園前景看法審慎,主因其槓桿較高。
中國奧園股價兩連跌,最低見2.12元,創逾四年低,現報2.14元,急挫逾15%,成交增至6,094萬股。奧園健康低見2.74元,創上市新低,現報2.84元,急挫24%,成交激增至4,209萬股,創近年半高。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.